TURNOVER (x1000 NOK)
NET PROFIT (x1000 NOK)
EMPLOYEES
Calliditas Therapeutics AB
Closing information (x1000 NOK)
Closing information | 2022/12 (consolidated) | 2021/12 (consolidated) | 2020/12 (consolidated) |
Turnover |
759,453
|
223,664
|
916 |
Financial expenses |
35,632
|
9,024
|
59,690 |
Earnings before taxes |
-387,273
|
-500,653
|
-456,912 |
EBITDA |
-386,907
|
-511,461
|
-394,838 |
Total assets |
1,847,342
|
1,423,737
|
1,578,159 |
Current assets |
1,335,822
|
987,678
|
1,086,207 |
Current liabilities |
307,639
|
132,090
|
110,647 |
Equity capital |
724,818
|
983,298
|
1,268,112 |
- share capital |
2,254
|
2,042
|
2,093 |
Employees (average) |
86
|
56
|
23 |
Financial ratios
Fiscal year | 2022/12 (consolidated) | 2021/12 (consolidated) | 2020/12 (consolidated) |
Solvency |
39.2%
|
69.1%
|
80.4% |
Turnover per employee |
8,831
|
3,994
|
40 |
Profit as a percentage of turnover |
-51.0%
|
-223.8%
|
-49881.2% |
Return on assets (ROA) |
-19.0%
|
-34.5%
|
-25.2% |
Current ratio |
434.2%
|
747.7%
|
981.7% |
Return on equity (ROE) |
-53.4%
|
-50.9%
|
-36.0% |
Change turnover |
542,511
|
222,812
|
-192,712 |
Change turnover % |
250%
|
26141%
|
-100% |
Chg. No. of employees |
30
|
33
|
9 |
Chg. No. of employees % |
54%
|
143%
|
64% |
Total value of public sale
Fiscal year | 2022/12 (consolidated) | 2021/12 (consolidated) | 2020/12 (consolidated) |
Total value of public sale |
0
![]() |
0
![]() |
0 |
Closing figures are converted to the currency above at the exchange rate of the closing date. Source for the exchange rates: Sveriges Riksbank
The closing information is gathered directly from the companies or from Creditsafe.